Vered Bisker-Leib, PHD, MBA
Vered Bisker-Leib is the Chief Business Officer of Compass Therapeutics. Prior to Compass, Vered served as an entrepreneur-in-residence with Atlas Ventures, where she provided business guidance to seed stage companies. Previously, she was the Chief Business Officer of Cydan, a biotech accelerator, where she co-founded biotech companies focused on therapies addressing rare diseases. Before joining Cydan, Vered was a member of Bristol-Myers Squibb’s strategic transactions group where she assumed roles of increasing responsibility across five therapeutic areas, most recently as an Executive Director and Global Head of business development, for the Cardiovascular and Metabolic franchises. She led a team responsible for creating the business development strategy and its execution, culminating in the licensing of pre-clinical and clinical stage programs from Alder, AmbrX, and Portola, and the acquisitions of ZymoGenetics, Amira Pharmaceuticals, and Amylin among others. Earlier in her career, Vered held business development roles at Avalon Pharmaceuticals and MedImmune after beginning her career as a scientist at Baxter.
Vered concurrently earned her PhD in Chemical Engineering and MBA from the University of Massachusetts, Amherst, where she was a Lois Pope MBA Scholar. She has a BSc in Chemical Engineering from the Israel Institute of Technology, Haifa.